1. Home
  2. CRSP vs FFIN Comparison

CRSP vs FFIN Comparison

Compare CRSP & FFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • FFIN
  • Stock Information
  • Founded
  • CRSP 2013
  • FFIN 1890
  • Country
  • CRSP Switzerland
  • FFIN United States
  • Employees
  • CRSP N/A
  • FFIN N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • FFIN Major Banks
  • Sector
  • CRSP Health Care
  • FFIN Finance
  • Exchange
  • CRSP Nasdaq
  • FFIN Nasdaq
  • Market Cap
  • CRSP 5.6B
  • FFIN 5.3B
  • IPO Year
  • CRSP 2016
  • FFIN N/A
  • Fundamental
  • Price
  • CRSP $67.35
  • FFIN $31.02
  • Analyst Decision
  • CRSP Buy
  • FFIN Hold
  • Analyst Count
  • CRSP 18
  • FFIN 3
  • Target Price
  • CRSP $73.47
  • FFIN $38.33
  • AVG Volume (30 Days)
  • CRSP 2.7M
  • FFIN 494.6K
  • Earning Date
  • CRSP 11-04-2025
  • FFIN 10-23-2025
  • Dividend Yield
  • CRSP N/A
  • FFIN 2.39%
  • EPS Growth
  • CRSP N/A
  • FFIN 16.51
  • EPS
  • CRSP N/A
  • FFIN 1.69
  • Revenue
  • CRSP $38,050,000.00
  • FFIN $581,881,000.00
  • Revenue This Year
  • CRSP N/A
  • FFIN $20.62
  • Revenue Next Year
  • CRSP $391.94
  • FFIN $6.83
  • P/E Ratio
  • CRSP N/A
  • FFIN $18.85
  • Revenue Growth
  • CRSP N/A
  • FFIN 14.03
  • 52 Week Low
  • CRSP $30.04
  • FFIN $30.50
  • 52 Week High
  • CRSP $78.48
  • FFIN $44.66
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 50.50
  • FFIN 33.26
  • Support Level
  • CRSP $64.80
  • FFIN $31.11
  • Resistance Level
  • CRSP $75.06
  • FFIN $32.75
  • Average True Range (ATR)
  • CRSP 4.55
  • FFIN 0.90
  • MACD
  • CRSP -0.96
  • FFIN -0.06
  • Stochastic Oscillator
  • CRSP 18.64
  • FFIN 14.81

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About FFIN First Financial Bankshares Inc.

First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto. It derives maximum revenue from Construction and Development Segment.

Share on Social Networks: